All In Biotech

Free tool

FAERS Monitor: Daliresp

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022522 or its brand name (Daliresp, Roflumilast). Reports on generic versions are filed under their own applications.

Reports

6,156

Serious

4,118

67% of reports

Hospitalization

2,056

Death reported

958

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea1,062
  • death743
  • chronic obstructive pulmonary disease669
  • diarrhoea539
  • pneumonia470
  • nausea461
  • weight decreased443
  • cough366
  • headache359
  • drug ineffective322
  • off label use317
  • dizziness300
  • asthma299
  • insomnia298
  • malaise288

Reports by year received

View as table
YearReports
20105
201177
2012676
2013493
2014460
2015396
2016427
2017325
2018329
2019389
2020360
2021336
2022341
2023448
2024341
2025391
2026362

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,003 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic obstructive pulmonary diseaseSignal66944.441.328,018
asthmaSignal2999.18.12,142
dyspnoeaSignal1,0626.46.14,979
weight decreasedSignal4435.45.01,615
pneumoniaSignal4705.04.61,506
coughSignal3664.54.0992
insomniaSignal2983.83.4626
deathSignal7432.92.8995
diarrhoeaSignal5392.92.6667
malaiseSignal2882.22.0202
dizzinessSignal3002.11.8165
nausea4612.01.8235
headache3592.01.8172
off label use3171.21.115
drug ineffective3220.80.811

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.